Cohort Study: Do Anticonvulsants Interfere with DOAC Therapy?

Navigate to this open-access population cohort study of the effects of anticonvulsants when used during DOAC Rx: Carlin S, Holbrook AM, Candeloro M, et al. Association of direct oral anticoagulant-anticonvulsant coprescription with clinical outcomes in older adults: a population-based cohort study. J Thromb Haemost. 2025:S1538-7836(25)00727-5. doi: 10.1016/j.jtha.2025.10.027. PMID: 41207565. Abstract Background: Anticonvulsants vary in their […]

Comments (0)

Anticoagulant Therapy

Jan 14 2026

george

Pilot Study: Oxerutin Therapy for Post-thrombotic Syndrome

Select this link to an open-access pilot study describing oxerutin, which is designed to reduce venous blockage after DVT: Iding AFJ, Hupperetz RD, Brans RJB, et al. Additional oxerutin therapy to promote deep vein thrombus resolution (RESOLVE-DVT): a randomized controlled pilot trial. J Thromb Haemost. 2025:S1538-7836(25)00718-4. doi: 10.1016/j.jtha.2025.10.018. PMID: 41197809. Abstract Background: Postthrombotic syndrome (PTS) […]

Thrombophilia

Review: The Effect of Exercise on Bleeding Disorders

This year is the 100th anniversary of the first VWD description, prompting several VWD updates, including Giuffrida AC, Gandini G, Focosi D, Franchini M. Impact of exercise/sport on well-being in von Willebrand disease and other congenital bleeding disorders: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9762. PMID: 41512904 available from your medical library. Abstract Worldwide, […]

Bleeding Disorders

Review: Desmopressin Therapy in Bleeding Disorders

Here is a 2025 open-access review that describes DDAVP Rx in hemophilia and VWD: Reardon B, Pasalic L, Favaloro EJ. A review of desmopressin use in bleeding disorders: an unsung hero? Biomolecules. 2025;15:967. doi: 10.3390/biom15070967. PMID: 40723839; PMCID: PMC12292229. Abstract As a synthetic analogue of vasopressin, desmopressin or DDAVP has well-established hemostatic properties. We present […]

Bleeding Disorders

VWD Type 2a Review

For an update on VWD type 2A, check with your medical library for Seidizadeh O, Baronciani L, Mannucci PM, Peyvandi F. Von Willebrand disease type 2A: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9989. PMID: 41453393. Abstract Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding […]

Bleeding Disorders

Anticoagulation Forum Archived Webinars

Fifth on our alphabetical Hemostasis Agencies list is the Anticoagulation Forum. The forum offers a lengthy list of archived educational webinars that describe a number of antithrombotic therapy issues. Click here for the forum’s webinar selection.

Comments (0)

Anticoagulant Therapy

Jan 1 2026

george

Reprise: Isolated Elevated D-dimer in an Apparently Healthy Individual

This question appeared 12-22-25 on the Diagnostic Equity page: “My D-dimer was elevated, but my CT scan ruled out a blood clot. What other conditions or factors can cause an elevated D-dimer, and then how should this result be interpreted in the context of my symptoms and overall health?“ This answer was provided by colleague Justin […]

Fibrinolysis

January 2026 Cheat Sheet

Click here for your January 2026 Fritsma Factor Cheat Sheet. If you would like a Cheat Sheet push copy that provides links to all the December, 2025 entries, please complete the Cheat Sheet application on the right. All Fritsma Factor services, sponsored by the PBI family of hemostasis in vitro diagnostic distributors, are free.

Cheat Sheets

January 2026 QQ: Fibrinolysis

Fibrinolysis plays a crucial role in the treatment of thrombosis. The components of fibrinolysis, in no particular order, are plasminogen, plasmin, TPA, TAFI, PAI-1, α2 antiplasmin, FDPs, and D-dimer. Our January 2026 Quick Question in the right column is a quiz that asks, “Which fibrinolysis enzyme digests fibrin?” Please select your answer, and feel free […]

Fibrinolysis

December 2025 QQ Results: Control Proteins

Our December 2025 Quick Question was a quiz that asked, “What plasma control protein acts against FIIa & FXa?” Here’s how our 34 respondents fared… Antithrombin: 27 (79%) Protein C: 5 (15%) Protein S: 1 (3%) Protein Z: 0 TFPI: 1 (3%) We scored well on this question. Antithrombin (AT), when activated by therapeutic heparin […]

Comments (0)

Coagulation Factors

All Posts

Cohort Study: Do Anticonvulsants Interfere with DOAC Therapy?

Pilot Study: Oxerutin Therapy for Post-thrombotic Syndrome

Review: The Effect of Exercise on Bleeding Disorders

Review: Desmopressin Therapy in Bleeding Disorders

VWD Type 2a Review

Anticoagulation Forum Archived Webinars

Reprise: Isolated Elevated D-dimer in an Apparently Healthy Individual

January 2026 Cheat Sheet

January 2026 QQ: Fibrinolysis

December 2025 QQ Results: Control Proteins

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question